COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00049322
Recruitment Status : Completed
First Posted : January 27, 2003
Results First Posted : March 15, 2016
Last Update Posted : September 1, 2020
National Cancer Institute (NCI)
Genentech, Inc.
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, cisplatin, and mitomycin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. Monoclonal antibodies, such as bevacizumab, can kill any tumor cells that are left after chemoembolization by blocking their ability to grow and spread.

PURPOSE: This randomized phase II trial is studying to see if chemoembolization followed by bevacizumab works better than chemoembolization alone in treating patients who have liver cancer that cannot be removed with surgery.

Condition or disease Intervention/treatment Phase
Liver Cancer Biological: bevacizumab Phase 2

Detailed Description:


  • Compare neovessel formation at 8 and 14 weeks after hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma treated with bevacizumab versus no bevacizumab (observation after chemoembolization only).
  • Compare time to progression, objective response rate, and tumor marker progression in patients treated with these regimens.
  • Determine the pharmacokinetics of bevacizumab in patients with liver function impairment.
  • Determine the toxic effects of this drug in these patients.
  • Compare the cancer biomarker pattern of peripheral blood cells and plasma before and after chemoembolization in patients treated with these regimens.

OUTLINE: This is a randomized, open-label study.

All patients receive hepatic artery chemotherapy (chemoembolization) comprising doxorubicin HCl liposome, cisplatin, and mitomycin on day 8 and possibly on day 92. Patients are then randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning 1 week prior to the first chemoembolization. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients do not receive bevacizumab. Patients in arm II may cross-over receive bevacizumab as in arm I if recurrent tumor is evident at week 14 by CT scan or MRI or a 50% or greater increase in AFP level has occurred since day 8 chemoembolization.

PROJECTED ACCRUAL: A total of 30 patients (15 per treatment arm) will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study Of rhuMAb VEGF (BEVACIZUMAB) In Patients With Hepatocellular Carcinoma Receiving Chemoembolization
Study Start Date : June 2003
Actual Primary Completion Date : February 2012
Actual Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Cancer
Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Arm I-bevacizumab
Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning 1 week prior to the first chemoembolization at a dose of 10 mg/kg. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
Biological: bevacizumab

Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.

Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose.

Other Name: Avastin

No Intervention: Arm II-chemoembolization
chemoembolization as part of standard of care

Primary Outcome Measures :
  1. Neovessel Formation as Measured by Angiogram at 14 Weeks [ Time Frame: 14 weeks ]
    Angiograms were assessed for changes in vascularity. The numbers indicate how many subjects in each group showed neovessel formation.

Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 16 weeks ]
    Progression free survival (PFS) at 16 weeks (end of the core phase).

  2. Assess the Toxicities of Bevacizumab in Patients With Liver Function Impairment [ Time Frame: 16 weeks ]
  3. Assess Pharmakokinetics of Bevacizumab in Liver Disease [ Time Frame: day 85 ]
    bevacizumab serum concentrations

  4. Measure (Vascular Endothelial Growth Factor)VEGF Before and After TACE With and Without Bevacizumab [ Time Frame: 21 days after TACE ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 year old
  • Histologically or cytologically documented HCC
  • Patients must have bi-dimensional measurable disease by CT or MRI scan that does not exceed 50% of the liver parenchyma
  • Patients must be considered clinical candidates for chemoembolization, with at least one lesion > 3cm and no lesion > 15cm in its longest diameter
  • Patients awaiting cadaveric orthotopic liver transplantation are eligible if they meet all other criteria. These patients must have a model for end-stage liver disease priority score < 28 points at entry
  • Cirrhosis Child-Pugh class A or B
  • Patients with documented grad III varices or prior history of UGI bleeding will require endoscopic evaluation prior to treatment under this protocol.
  • Platelet count equal or greater than 60,000/μL
  • Female patients must use effective contraception, be surgically sterile or be postmenopausal; male patients must be using barrier contraception or be surgically sterile
  • Patients must be willing and able to comply with all study requirements and have signed the informed consent

Exclusion Criteria:

  • Previous history of liver transplantation
  • Fibrolamellar histology
  • Prior antiangiogenesis therapy
  • Presence of extrahepatic disease
  • Presence of biliary obstruction defined as biliary dilatation and total bilirubin > 2.5mg/dl
  • Thrombosis of the main portal vein
  • Absolute contraindications to doxorubicin, mitomycin-C, cisplatin, iodinated contrast material, Avitene or dexamethasone treatment
  • Other active malignancies during the past year (except for non-melanoma skin cancer or in situ carcinomas)
  • ECOG PS> 2 or life expectancy < 12 weeks
  • History or evidence upon physical examination of CNS disease
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure within 3 months of study entry; fine needle aspirations within 7 days prior to Day 0
  • Current or recent (within the 10 days prior to Day 0) use of full-dose oral or parenteral anticoagulants (except as required to maintain patency of preexisting, permanent indwelling IV catheters) or thrombolytic agent (for subjects receiving warfarin, international normalized ration of < 1.5)
  • Chronic, daily treatment with aspirin (> 325mg/day) or nonsteroidal anti-inflammatory medications
  • Positive pregnancy test or lactation
  • Proteinuria at baseline or clinically significant impairment of renal function. Subjects unexpectedly discovered to have > 1+ proteinuria at baseline should undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate < 500 mg of protein/24 hr to allow participation in the study
  • Serious, nonhealing wound, ulcer, or bone fracture
  • Evidence of bleeding diathesis or coagulopathy
  • Current or recent (within the 28 days prior to Day 0) participation in another experimental drug study
  • Clinically significant cardiovascular disease, New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year prior to Day 0
  • Prior history of hypertensive crisis of hypertensive encephalopathy
  • History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1
  • History of hemoptysis within 1 month prior to Day 1
  • Significant vascular disease within 6 months prior to Day 1
  • Screening clinical laboratory values:

    • ANC of < 1500/μL
    • INR of > 1.5
    • Total bilirubin of > 2.5mg/dL
    • AST or ALT > 5 times upper limit of normal
    • Serum creatinine of > 2.0 mg/dL or creatinine clearance < 45 mL/min
    • Hemoglobin of < 8.5 gm/dL
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00049322

Layout table for location information
United States, California
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Carolyn Britten, MD Jonsson Comprehensive Cancer Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00049322    
Other Study ID Numbers: CDR0000258045
UCLA-0206060 ( Other Identifier: UCLA )
NCI-G02-2124 ( Other Identifier: NCI )
First Posted: January 27, 2003    Key Record Dates
Results First Posted: March 15, 2016
Last Update Posted: September 1, 2020
Last Verified: February 2016
Keywords provided by Jonsson Comprehensive Cancer Center:
localized unresectable adult primary liver cancer
recurrent adult primary liver cancer
adult primary hepatocellular carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors